ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Orchard’s OTL-101 receives promising medicine designation for ADA-SCID in UK
August 24, 2017Biotechnology company Orchard Therapeutics’ OTL-101 has received a promising innovative medicine designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of adenosine deaminase severe combined immunodeficiency. -
Orchard Therapeutics signs manufacturing services agreement with PCT Cell Therapy Services
June 02, 2017Under the terms of this new agreement, PCT will provide GMP-compliant manufacturing services for Orchard’s lead product, OTL-101, an autologous ex-vivo gene therapy for the treatment of ADA-SCID.
Pharma Sources Insight January 2025
